Abstract | BACKGROUND: OBJECTIVE: We sought to review case reports of drug-induced DM. METHODS: Articles were gathered from MEDLINE and bibliographies of acquired reports. Causality was assessed using World Health Organization criteria. Clinical characteristics, management, and resolution were examined. RESULTS: In 70 reported cases, 50% of patients were female and the median age was 57 years. Hydroxyurea was implicated in 51% of cases. All cases had pathognomonic (76%) or compatible (24%) cutaneous findings. Hydroxyurea cases lacked myositis, but myositis was described in 79.4% of nonhydroxyurea cases. Drug causality was probable (25.7%) or possible (74.3%), but not certain in any case. Most patients had underlying pathology associated with DM (44% had malignancy; 16% had rheumatoid arthritis). Of the sample, 84.3% had improvement of DM after discontinuation of the drug. LIMITATIONS: Case reports may emphasize unusual findings. CONCLUSIONS: Further work is needed to differentiate drug effects from underlying, predisposing factors.
|
Authors | Anne M Seidler, Alice B Gottlieb |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 59
Issue 5
Pg. 872-80
(Nov 2008)
ISSN: 1097-6787 [Electronic] United States |
PMID | 18625537
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Antinuclear
- Etoposide
- Cyclophosphamide
- Hydroxyurea
|
Topics |
- Adult
- Aged
- Antibodies, Antinuclear
(analysis)
- Autoimmune Diseases
(drug therapy)
- Cyclophosphamide
(adverse effects)
- Dermatomyositis
(chemically induced, pathology)
- Etoposide
(adverse effects)
- Female
- Humans
- Hydroxyurea
(adverse effects)
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(complications, drug therapy)
- Male
- Middle Aged
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy)
- Skin
(pathology)
|